Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Discover How Success by Sesame’s Affordable, Telehealth-Driven Weight Loss Program Combines Compounded Semaglutide, ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

With pharmaceutical GLP-1 drugs like semaglutide in high demand, Metamorphx offers a plant-based alternative designed to ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

The metabolic effects of weight management medicines extend beyond appetite regulation. Still, with more questions about ...

The review concluded that semaglutide was well tolerated and effective for weight loss in STEP 4 and 5 trials, with a confirmed benefit to the continued use of semaglutide for sustained weight ...

The Food and Drug Administration (FDA) has accepted for review the New ... of patients who achieved body weight loss of 5% or more. Safety and tolerability of semaglutide 25 mg were consistent ...